Were Analysts Bullish Ergomed plc (LON:ERGO) This Week?

June 14, 2018 - By Lindsey Sherman

Ergomed plc (LON:ERGO) Ratings Coverage

Among 2 analysts covering Ergomed (LON:ERGO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ergomed has GBX 300 highest and GBX 300 lowest target. GBX 300’s average target is 24.22% above currents GBX 241.5 stock price. Ergomed had 5 analyst reports since December 15, 2017 according to SRatingsIntel. The rating was maintained by Numis Securities with “Buy” on Monday, March 5. The company was maintained on Thursday, February 1 by Numis Securities. Numis Securities maintained the shares of ERGO in report on Wednesday, April 11 with “Buy” rating. N+1 Singer maintained Ergomed plc (LON:ERGO) on Friday, December 15 with “Corporate” rating. Numis Securities maintained the stock with “Buy” rating in Thursday, January 25 report. Below is a list of Ergomed plc (LON:ERGO) latest ratings and price target changes.

11/04/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
05/03/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
01/02/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
25/01/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 300.00 New Target: GBX 300.00 Maintain
15/12/2017 Broker: N+1 Singer Rating: Corporate Maintain

The stock decreased 0.21% or GBX 0.5 during the last trading session, reaching GBX 241.5. About 5,722 shares traded. Ergomed plc (LON:ERGO) has 0.00% since June 14, 2017 and is . It has underperformed by 12.57% the S&P500.

Ergomed plc provides clinical research, and drug development and safety services in the United Kingdom and rest of Europe, the Middle East, Africa, North America, Asia, and Australia. The company has market cap of 108.22 million GBP. The firm offers clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It currently has negative earnings. It focuses on various therapeutic areas, including oncology, neurology, and immunology, as well as the development of orphan drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.